Clinical Trial · NCT01582204

Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma

Overview

Usually, doctors monitor kidney cancer with CT scans to measure the size of tumors. Sometimes, even when a drug is working, it can take several months before the effects are seen on a regular CT scan. The purpose of this study is to see if a new kind of scan, called 124I-cG250 PET/CT, can determine response to sunitinib or pazopanib earlier than a regular CT scan. Research has shown that certain proteins in the blood, called antibodies, can attach themselves to cancer cells without binding to normal cells. In this study, an antibody is used called chimeric G250 (cG250) that is attached to a radioactive isotope. The radioactive isotope in this study is Iodine-124 (124I). If cG250 has attached to tumors in the body, 124I shows up on the PET scan.

Sponsor

Memorial Sloan Kettering Cancer Center

Phase

N/A

Contacts

Darren Feldman, MD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT01582204

Drug / Compound

cG250

Isotope(s):

Target(s):

CAIX

Ligand Class: Antibodies

Eligibility

Inclusion

Histologically confirmed clear cell carcinoma (conventional) with advanced and/or metastatic disease.
Radiographic evidence of unidimensionally measurable disease. Lesions will be considered measurable or non- measurable as per definitions provided in RECIST version 1.1
Subjects must be planned for treatment with approved treatment doses of a VEGF receptor TKI (e.g., sunitinib, pazopanib, cabozantinib, axitinib, sorafenib, lenvatinib).

Exclusion

Exclusion criteria not yet provided.